Abstract:e16253 Background: Hepatocellular carcinoma (HCC) is a highly lethal and aggressive malignant tumor characterized by high rates of recurrence and metastasis, and low survival outcomes. The current treatments available for HCC have shown limited success, and the prevalence of genomic characterization and their association with survival and recurrence in HCC patients are largely unknown. Methods: The investigation enrolled 1,221 Chinese individuals diagnosed with primary HCC. This study collected samples including tumor and paired tumor-free tissues and clinical characteristics. Among them, 348 patients' clinical outcome data, including overall survival (OS) and recurrence-free survival (RFS) were gathered. Genomic analysis was conducted through panel sequencing by OrigiMed. Hazard ratios were calculated employing both univariate and multivariate Cox proportional hazards regression models. The log-rank test and Kaplan-Meier plots were used to assess comparison of clinical outcomes by various prognostic factors. For other statistical analyses, a two-tailed unpaired t-test and Fisher's exact test were applied. Results: With a median age of 54, 87% of the cases were male. Pertaining to risk factors, 74% cases had HBV infection and 62% cases were cirrhosis. Meanwhile, serum AFP levels greater (or less) than 400 ng/mL were present in 299 cases (or 485 cases). Panel sequencing identified the most prevalent mutations ( > 10%, excluding copy number variations) in TP53 (60%), TERT (40%), CTNNB1 (21%), AXIN1 (14%), LRP1B (14%), ARID1A (13%), RB1 (12%) and TSC2 (11%). The most frequently amplified genes were located at chr11q13, including CCND1 (9%), FGF19 (9%), FGF4 (7%) and FGF3 (7%). Survival analysis indicated that patients with Chr11q13 amp had significantly shorter OS and RFS. Further studies revealed a higher incidence of Chr11q13 amp in patients at advanced stages III/IV (64/564, 11%) compared to early-stage I/II (38/523, 7%), and in patients with vascular invasion (31/220, 14%) versus those without (44/599, 7%). No significant differences were observed in tumor mutational burden and HLA-I evolutionary divergence between patients with various Chr11q13 amp statuses. Furthermore, multivariate Cox proportional hazards regression models were utilized to examine the relationship between Chr11q13 amp status, characteristics and outcomes. Among the 248 patients with comprehensive clinical characteristics and available OS and RFS data, analyses indicated significant negative correlations between Chr11q13 amp and embolus with both OS and RFS. Conclusions: Our study elucidates that the presence of Chr11q13 amp was significantly associated with worse survival and increased risk of recurrence among a large cohort of Chinese patients with HCC. This discovery yields important insights into the understanding of HCC and has the potential to benefit personalized therapy.

TP53 R249S mutation detected in circulating tumour DNA is associated with Prognosis of hepatocellular carcinoma patients with or without hepatectomy

Association of TP53 Mutations with Stem Cell-Like Gene Expression and Survival of Patients with Hepatocellular Carcinoma.

Genome-wide Association Study of the TP53 R249S Mutation in Hepatocellular Carcinoma with Aflatoxin B1 Exposure and Infection with Hepatitis B Virus

Establishment of a Prognostic Model for Predicting Short-Term Disease-Free Survival in Cases of Hepatitis B-related Hepatocellular Carcinoma with the TP53 249ser Mutation in Southern China

Caspase Polymorphisms and Prognosis of Hepatocellular Carcinoma

Abstract 1983: TP53 Mutations in Hepatocellular Carcinoma: Association with Survival and Stem Cell-Like Gene Expression Traits

The Diagnostic and Prognostic Usage of Circulating Tumor DNA in Operable Hepatocellular Carcinoma.

LRP1B or TP53 Mutations Are Associated with Higher Tumor Mutational Burden and Worse Survival in Hepatocellular Carcinoma.

TP53 and CDKN2A mutations in patients with early-stage lung squamous cell carcinoma: an analysis of the correlations and prognostic outcomes

Prognostic Impact Of Mutation Profiling In Chinese Patients With Colorectal Liver Metastases.

[Clinical Features and Prognostic Value of TP53 Mutation in Chinese Prostate Cancer Patients].

Association of Chr11q13 Amplification with Survival and Recurrence in Patients with Surgically Treated Hepatocellular Carcinoma.

3‐Mercaptopyruvate sulfurtransferase represses tumour progression and predicts prognosis in hepatocellular carcinoma

TP53 mutation-related senescence is an indicator of hepatocellular carcinoma patient outcomes from multiomics profiles.

Serial Circulating Tumor DNA to Predict Early Recurrence in Patients with Hepatocellular Carcinoma: a Prospective Study.

Prognostic Value of Postoperative Circulating Tumor DNA in Patients With Early- and Intermediate-Stage Hepatocellular Carcinoma

Genomic landscape of Chinese patients with hepatocellular carcinoma using next-generation sequencing and its association with the prognosis

Genomic profiling informs therapies and prognosis for patients with hepatocellular carcinoma in clinical practice

Prognosis and personalized treatment prediction in TP53 -mutant hepatocellular carcinoma: an in silico strategy towards precision oncology

Identification and development of TP53 mutation-associated Long non-coding RNAs signature for optimized prognosis assessment and treatment selection in hepatocellular carcinoma

Detection of TP53 gene mutation in blood of breast cancer patients based on circulating tumor DNA and its application in prognosis